1. Home
  2. TIL vs EPRX Comparison

TIL vs EPRX Comparison

Compare TIL & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TIL
  • EPRX
  • Stock Information
  • Founded
  • TIL 2018
  • EPRX 2011
  • Country
  • TIL United States
  • EPRX Canada
  • Employees
  • TIL N/A
  • EPRX N/A
  • Industry
  • TIL Biotechnology: Pharmaceutical Preparations
  • EPRX
  • Sector
  • TIL Health Care
  • EPRX
  • Exchange
  • TIL Nasdaq
  • EPRX NYSE
  • Market Cap
  • TIL 134.5M
  • EPRX 109.7M
  • IPO Year
  • TIL 2021
  • EPRX N/A
  • Fundamental
  • Price
  • TIL $20.97
  • EPRX $3.20
  • Analyst Decision
  • TIL Strong Buy
  • EPRX Strong Buy
  • Analyst Count
  • TIL 4
  • EPRX 1
  • Target Price
  • TIL $114.00
  • EPRX $9.00
  • AVG Volume (30 Days)
  • TIL 103.6K
  • EPRX 6.9K
  • Earning Date
  • TIL 11-13-2024
  • EPRX 02-07-2025
  • Dividend Yield
  • TIL N/A
  • EPRX N/A
  • EPS Growth
  • TIL N/A
  • EPRX N/A
  • EPS
  • TIL N/A
  • EPRX N/A
  • Revenue
  • TIL N/A
  • EPRX N/A
  • Revenue This Year
  • TIL N/A
  • EPRX N/A
  • Revenue Next Year
  • TIL $2.65
  • EPRX N/A
  • P/E Ratio
  • TIL N/A
  • EPRX N/A
  • Revenue Growth
  • TIL N/A
  • EPRX N/A
  • 52 Week Low
  • TIL $9.20
  • EPRX $2.20
  • 52 Week High
  • TIL $92.00
  • EPRX $4.08
  • Technical
  • Relative Strength Index (RSI)
  • TIL 46.36
  • EPRX N/A
  • Support Level
  • TIL $18.56
  • EPRX N/A
  • Resistance Level
  • TIL $22.00
  • EPRX N/A
  • Average True Range (ATR)
  • TIL 1.98
  • EPRX 0.00
  • MACD
  • TIL 0.36
  • EPRX 0.00
  • Stochastic Oscillator
  • TIL 28.05
  • EPRX 0.00

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

About EPRX EUPRAXIA PHARMACEUTICALS INC

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with significant unmet medical needs.

Share on Social Networks: